JP5602366B2 - β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン - Google Patents

β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン Download PDF

Info

Publication number
JP5602366B2
JP5602366B2 JP2008538454A JP2008538454A JP5602366B2 JP 5602366 B2 JP5602366 B2 JP 5602366B2 JP 2008538454 A JP2008538454 A JP 2008538454A JP 2008538454 A JP2008538454 A JP 2008538454A JP 5602366 B2 JP5602366 B2 JP 5602366B2
Authority
JP
Japan
Prior art keywords
virus
dna
vaccine
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008538454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513694A (ja
JP2009513694A5 (enExample
Inventor
ジェンス−ペーター グレゲルセン，
ホルゲル コスト，
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5602366(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー
Publication of JP2009513694A publication Critical patent/JP2009513694A/ja
Publication of JP2009513694A5 publication Critical patent/JP2009513694A5/ja
Application granted granted Critical
Publication of JP5602366B2 publication Critical patent/JP5602366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008538454A 2005-11-01 2006-11-01 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン Active JP5602366B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
US60/732,786 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011206634A Division JP2011256209A (ja) 2005-11-01 2011-09-21 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
JP2014149517A Division JP6639077B2 (ja) 2005-11-01 2014-07-23 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン

Publications (3)

Publication Number Publication Date
JP2009513694A JP2009513694A (ja) 2009-04-02
JP2009513694A5 JP2009513694A5 (enExample) 2011-11-10
JP5602366B2 true JP5602366B2 (ja) 2014-10-08

Family

ID=37969762

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2008538454A Active JP5602366B2 (ja) 2005-11-01 2006-11-01 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
JP2011206634A Withdrawn JP2011256209A (ja) 2005-11-01 2011-09-21 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
JP2014149517A Active JP6639077B2 (ja) 2005-11-01 2014-07-23 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
JP2016145286A Active JP7049761B2 (ja) 2005-11-01 2016-07-25 β－プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
JP2019192740A Pending JP2020023557A (ja) 2005-11-01 2019-10-23 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011206634A Withdrawn JP2011256209A (ja) 2005-11-01 2011-09-21 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
JP2014149517A Active JP6639077B2 (ja) 2005-11-01 2014-07-23 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
JP2016145286A Active JP7049761B2 (ja) 2005-11-01 2016-07-25 β－プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン
JP2019192740A Pending JP2020023557A (ja) 2005-11-01 2019-10-23 β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン

Country Status (19)

Country Link
US (2) US10655108B2 (enExample)
EP (3) EP2842572A1 (enExample)
JP (5) JP5602366B2 (enExample)
KR (1) KR20080081254A (enExample)
CN (2) CN101365480B (enExample)
AT (1) ATE494906T1 (enExample)
AU (2) AU2006310171B2 (enExample)
CA (1) CA2627971A1 (enExample)
CY (1) CY1111378T1 (enExample)
DE (1) DE602006019629D1 (enExample)
DK (1) DK1951296T4 (enExample)
EA (1) EA014062B1 (enExample)
ES (2) ES2525518T3 (enExample)
HK (1) HK1207828A1 (enExample)
NZ (1) NZ567817A (enExample)
PL (2) PL2301572T3 (enExample)
PT (1) PT2301572E (enExample)
SI (1) SI1951296T2 (enExample)
WO (1) WO2007052163A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014198726A (ja) * 2005-11-01 2014-10-23 ノバルティス ヴァクシンズ アンド ダイアグノスティク β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1976559T6 (pl) 2006-01-27 2020-08-10 Novartis Influenza Vaccines Marburg Gmbh Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
EP2066345B1 (en) 2006-09-11 2015-02-25 Novartis AG Making influenza virus vaccines without using eggs
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US20110014230A1 (en) 2008-03-18 2011-01-20 Novartis Ag preparation of influenza virus vaccine antigens
CA2741961A1 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
JP2012525370A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー インフルエンザに対して防御するためのアジュバント添加ワクチン
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
JP2013500712A (ja) 2009-07-31 2013-01-10 ノバルティス アーゲー 逆遺伝学系
CN102648003B (zh) 2009-10-09 2016-01-13 儿童医疗中心有限公司 选择性裂解的全细胞疫苗
NZ599479A (en) 2009-10-20 2013-11-29 Novartis Ag Improved reverse genetics methods for virus rescue
BR112012027643A2 (pt) 2010-05-03 2016-08-16 Glaxosmithkline Biolog Sa métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica
KR20130079398A (ko) 2010-05-06 2013-07-10 노파르티스 아게 미생물 불활성화를 위한 유기 과산화 화합물
CA2800150C (en) 2010-05-21 2018-09-04 Novartis Ag Influenza virus reassortment method
ES2825712T3 (es) 2010-06-01 2021-05-17 Seqirus Uk Ltd Concentración de antígenos de vacuna contra la influenza sin liofilización
CN102939104A (zh) 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
CN103052399B (zh) 2010-08-12 2016-06-29 依生生物制药控股有限公司 用于减少病毒组合物中dna杂质的方法
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
KR20140006963A (ko) 2011-02-25 2014-01-16 노파르티스 아게 외래 내부 양성 대조군
EP3290050B1 (en) 2011-11-03 2019-01-02 Sentinext Therapeutics SDN BHD Vaccines directed against human enteroviruses
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
CA2813723A1 (en) 2012-03-02 2013-09-02 Novartis Ag Influenza virus reassortment
JP5918870B2 (ja) 2012-03-06 2016-05-18 クルセル ホランド ベー ヴェー インフルエンザに対する改善されたワクチン接種
AU2013270793A1 (en) 2012-06-04 2014-12-11 Novartis Ag Improved safety testing
EP2925356A2 (en) 2012-12-03 2015-10-07 Novartis AG Reassortant influenza a viren
JP6525469B2 (ja) 2013-03-13 2019-06-05 ノバルティス アーゲー インフルエンザｂ型ウイルス再集合
CA2911296A1 (en) 2013-05-10 2014-11-13 Wayne Volkmuth Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
US10329537B2 (en) 2013-06-06 2019-06-25 Seqirus UK Limited Influenza virus reassortment
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
WO2015071177A1 (en) 2013-11-15 2015-05-21 Novartis Ag Removal of residual cell culture impurities
CN106661102B (zh) * 2014-05-28 2021-01-26 财团法人卫生研究院 作为对抗肠病毒感染之免疫原的病毒颗粒及其制造
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
EP4054630A2 (en) * 2019-11-07 2022-09-14 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size
AU2020389047A1 (en) 2019-11-18 2022-06-02 Seqirus Pty Ltd. Method for producing reassortant influenza viruses
AU2022251654A1 (en) * 2021-03-30 2023-10-12 Denka Company Limited Influenza vaccine
CN115354071A (zh) * 2022-08-10 2022-11-18 上海药明生基医药科技有限公司 一种检测重组腺相关病毒宿主细胞dna残留的方法
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用
TW202516000A (zh) * 2023-07-25 2025-04-16 日商Ｋｍ生物醫藥股份有限公司 利用雞蛋培養法進行的去活化流感疫苗的製備方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (enExample) * 1974-01-14 1977-07-15 Sandoz Ag
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
EP0251575B2 (en) 1986-06-17 2002-11-13 Chiron Corporation Hepatitis delta diagnostics and vaccines, their preparation and use
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
JP4610735B2 (ja) * 1998-06-01 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ワクチン抗原およびアジュバントの粘膜送達のためのヒアルロン酸ポリマーの使用
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
EP1187629B1 (en) * 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE60036952T2 (de) 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
WO2001041814A1 (en) 1999-12-08 2001-06-14 Crucell Holland B.V. Method of administering adenovirus
JP4698112B2 (ja) 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
JP5208347B2 (ja) * 2001-02-23 2013-06-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
WO2002087494A2 (en) 2001-04-27 2002-11-07 Glaxosmithkline Biologicals, Sa Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP2497826A1 (en) 2002-04-26 2012-09-12 MedImmune, LLC Method of producing a temperature sensitive (ts) influenza virus
EP1590450A2 (en) 2002-12-20 2005-11-02 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
CA2522379C (en) 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
NZ543446A (en) 2003-05-28 2008-06-30 Wisconsin Alumni Res Found High titer recombinant influenza viruses for vaccines and gene therapy
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1780269B1 (en) 2004-02-23 2009-07-08 Crucell Holland B.V. Virus purification methods
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
SI2236155T1 (sl) * 2004-09-09 2012-09-28 Novartis Vaccines & Diagnostic Zmanjšanje potencialnih iatrogenih tveganj, povezanih s cepivi proti influenci
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EP2842572A1 (en) * 2005-11-01 2015-03-04 Novartis Vaccines and Diagnostics GmbH Cell-derived viral vaccines with low levels of residual cell dna
SG174813A1 (en) * 2006-09-15 2011-10-28 Medimmune Llc Mdck cell lines supporting viral growth to high titers and bioreactor process using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014198726A (ja) * 2005-11-01 2014-10-23 ノバルティス ヴァクシンズ アンド ダイアグノスティク β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン

Also Published As

Publication number Publication date
EP2301572A1 (en) 2011-03-30
AU2011201968A1 (en) 2011-05-19
KR20080081254A (ko) 2008-09-09
AU2011201968B2 (en) 2014-08-28
BRPI0618094A2 (pt) 2011-08-16
WO2007052163A3 (en) 2007-09-07
JP6639077B2 (ja) 2020-02-05
ES2525518T3 (es) 2014-12-26
DK1951296T3 (da) 2011-03-28
US20090304729A1 (en) 2009-12-10
AU2006310171B2 (en) 2011-02-17
US10655108B2 (en) 2020-05-19
JP2011256209A (ja) 2011-12-22
CN104474543A (zh) 2015-04-01
DE602006019629D1 (de) 2011-02-24
PL1951296T5 (pl) 2015-06-30
JP2009513694A (ja) 2009-04-02
CN101365480B (zh) 2014-11-05
ES2359214T3 (es) 2011-05-19
BRPI0618094A8 (pt) 2017-08-22
EP2301572B1 (en) 2014-09-10
JP2014198726A (ja) 2014-10-23
ES2359214T5 (es) 2014-10-08
EA200801221A1 (ru) 2008-10-30
PL2301572T3 (pl) 2015-02-27
ATE494906T1 (de) 2011-01-15
CN101365480A (zh) 2009-02-11
EP1951296A2 (en) 2008-08-06
US11466257B2 (en) 2022-10-11
JP2016185988A (ja) 2016-10-27
PT2301572E (pt) 2014-12-22
EA014062B1 (ru) 2010-08-30
CA2627971A1 (en) 2007-05-10
PL1951296T3 (pl) 2011-09-30
US20200377864A1 (en) 2020-12-03
WO2007052163A2 (en) 2007-05-10
SI1951296T1 (sl) 2011-04-29
SI1951296T2 (sl) 2014-09-30
EP1951296B1 (en) 2011-01-12
NZ567817A (en) 2012-01-12
JP7049761B2 (ja) 2022-04-07
EP2842572A1 (en) 2015-03-04
JP2020023557A (ja) 2020-02-13
HK1207828A1 (en) 2016-02-12
EP1951296B2 (en) 2014-07-23
CY1111378T1 (el) 2015-08-05
DK1951296T4 (da) 2014-09-01
HK1129837A1 (en) 2009-12-11
AU2006310171A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
US11466257B2 (en) Cell-derived viral vaccines with low levels of residual cell DNA
JP2009513694A5 (enExample)
ES3031467T3 (en) Making influenza virus vaccines without using eggs
JP6082483B2 (ja) インフルエンザウイルス再集合方法
JP5518041B2 (ja) インフルエンザウイルスワクチン抗原の調製における改良
JP2016104004A (ja) ウイルスレスキューのための改善された逆遺伝学
JP2016506724A (ja) インフルエンザウイルスの再集合
HK1153955A (en) Cell-derived viral vaccines with low levels of residual cell dna
HK1129837B (en) Cell-derived viral vaccines with low levels of residual cell dna
BRPI0618094B1 (pt) Método para preparar um produto de cultura de célula

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110628

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120427

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140820

R150 Certificate of patent or registration of utility model

Ref document number: 5602366

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250